IDNA:NYE-iShares Genomics Immunology and Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 19.02

Change

0.00 (0.00)%

Market Cap

USD 0.12B

Volume

0.06M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-12 )

ETFs Containing IDNA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -15.95% 19% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.95% 19% F 21% F
Trailing 12 Months  
Capital Gain -16.21% 14% F 22% F
Dividend Return 0.49% 44% F 7% C-
Total Return -15.72% 14% F 20% F
Trailing 5 Years  
Capital Gain -31.85% 10% F 12% F
Dividend Return 3.28% 53% F 6% D-
Total Return -28.57% 10% F 10% F
Average Annual (5 Year Horizon)  
Capital Gain -9.72% 5% F 7% C-
Dividend Return -9.16% 5% F 6% D-
Total Return 0.56% 53% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 25.72% 14% F 39% F
Risk Adjusted Return -35.61% 5% F 8% B-
Market Capitalization 0.12B 60% D- 29% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.